DWTX logo

DOGWOOD THERAPEUTICS INC

DWTXNASDAQ
🏆 #4489 by market capEarnings Nov 4US Equity
$800.56▼ $33.86 (−4.23%)
Simulated price
🔔
Track DWTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.2%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$46M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair
No chart data available for DWTX.

Trading Snapshot

Day Range
$788.61 – $809.28
52-Week Range
$1.28 – $9.50
Volume
$5.51B
Avg Volume
$5.37B
Shares Outstanding
33.6M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
-0.2
P/S Ratio
0.0x
EPS (TTM)
$-1.06
Dividend Yield
0.00%
Dilution (1yr)
+1008.1%

Why Investors Own DWTX

  • ✓High-growth profile — revenue up +41.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 30% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DWTX logo

DOGWOOD THERAPEUTICS INC

DWTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$28M▲ +128.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$16M▲ +77.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
14.5M▲ +1008.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$7M YoY
StockOtter · stockotter.space

About DOGWOOD THERAPEUTICS INC

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$985.55
▲ +23.1% Upside
High Target$1,230.57
Low Target$809.12
Based on 32 analysts

Latest News & Updates

🚀
Reuters·2h ago

DOGWOOD THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift DWTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

DOGWOOD THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.